[1]张立弋,常宝成,单春艳,等.SIRT1与糖尿病相关肿瘤的关系[J].国际内分泌代谢杂志,2017,37(06):418-421.
 Zhang Liyi,Chang Baocheng,Shan Chunyan,et al.Association of SIRT1 with diabetes-related tumors[J].International Journal of Endocrinology and Metabolism,2017,37(06):418-421.
点击复制

SIRT1与糖尿病相关肿瘤的关系()
分享到:

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
37
期数:
2017年06期
页码:
418-421
栏目:
综述
出版日期:
2017-11-20

文章信息/Info

Title:
Association of SIRT1 with diabetes-related tumors
作者:
张立弋常宝成单春艳孔岩刘海逸杨菊红
300070 天津医科大学代谢病医院糖尿病肾病科,卫生部激素与发育重点实验室
Author(s):
Zhang Liyi Chang Baocheng Shan Chunyan Kong Yan Liu Haiyi Yang Juhong.
Department of Diabetic Nephrology, The Metabolic Disease Hospital of Tianjin Medical University, Key Laboratory of the Ministry of Health of Hormones and Development, Tianjin 300070, China
关键词:
沉默信息调节因子1 2型糖尿病 恶性肿瘤 高胰岛素血症 慢性炎症
Keywords:
Silent information regulator 1 Type 2 diabetes mellitus Malignant tumor Hyperinsulinemia Chronic inflammation
文献标志码:
A
摘要:
糖尿病不仅增加肿瘤的患病风险,而且促进肿瘤的复发和转移。沉默信息调节因子1(SIRT1)是机体的能量感受器,具有调节糖、脂代谢,抑制慢性非特异性炎性反应,改善胰岛素抵抗等作用,其表达及活性异常参与了糖尿病及其并发症的发生。同时近期研究发现SIRT1也与肿瘤的发生、发展密切相关。通过去乙酰化调节机制SIRT1可调控大量转录因子及组蛋白的活性,从而参与染色质沉默、细胞凋亡、自噬途径及DNA损伤修复的调控,是联系细胞能量代谢与染色质结构的关键蛋白,因而可能是联系糖尿病及糖尿病相关肿瘤的重要中介。积极干预糖尿病患者中SIRT1信号途径异常,可能具有降低肿瘤风险的作用。
Abstract:
It is reported that diabetes increases the prevalence of tumors and promotes the recurrence and metastasis of tumors. Silent information regulator 1(SIRT1), the energy sensor of cells, play important roles in the regulations of glucolipid metabolism, inhibition of chronic non-specific inflammatory response, the improvement of insulin resistance. The abnormal expression and activities of SIRT1 play roles in diabetes and its complications. Recent studies also have found that SIRT1 acts in the initiation and progress of tumors. Through its deacetylation regulatory mechanism, SIRT1 regulates the activities of many transcription factors and histone, and therefore is involved in a large number of physiologic process of cells including chromatin silencing, apoptosis, autophagy, and the repair of DNA damage. SIRT1 is a key protein in the coupling of energy metabolism and chromatin structure. Therefore, SIRT1 may be a key player bridging diabetes and diabetes-related tumors, and active intervention targeting the abnormal SIRT1 signaling pathways may reduce the risk of tumor in diabetes.

参考文献/References:

[1] Palu RA, Thummel CS. Sir2 acts through hepatocyte nuclear factor 4 to maintain insulin signaling and metabolic homeostasis in drosophila[J].PLoS Genet,2016,12(4):e1005978. DOI:10.1371/journal.pgen.1005978.
[2] Meng X, Tan J, Li M, et al. Sirt1: role under the condition of ischemia/hypoxia[J].Cell Mol Neurobiol,2017,37(1):17-28. DOI:10.1007/s10571-016-0355-2.
[3] Zhang ZH, Su PY, Hao JH, et al. The role of preexisting diabetes mellitus on incidence and mortality of endometrial cancer: a meta-analysis of prospective cohort studies[J].Int J Gynecol Cancer,2013,23(2):294-303.DOI:10.1097/IGC.0b013e31827b8430.
[4] Fang H, Yao B, Yan Y,et al. Diabetes mellitus increases the risk of bladder cancer: an updated meta-analysis of observational studies[J].Diabetes Technol Ther,2013,15(11):914-922.DOI:10.1089/dia.2013.0131.
[5] Toriola AT, Stolzenberg-Solomon R, Dalidowitz L, et al. Diabetes and pancreatic cancer survival: a prospective cohort-based study[J].Br J Cancer,2014,111(1):181-185. DOI:10.1038/bjc.2014.224.
[6] Meyerhardt JA, Catalano PJ, Haller DG, et al. Impact of diabetes mellitus on outcomes in patients with colon cancer[J]. J Clin Oncol,2003,21(3):433-440.DOI:10.1200/jco.2003.07.125.
[7] Wang RH, Zheng Y, Kim HS,et al. Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis[J]. Mol Cell,2008,32(1):11-20. DOI:10.1016/j.molcel.2008.09.011.
[8] Howitz KT, Bitterman KJ, Cohen HY, et al.Small molecule activators of sirtuins extend Saccharomyces cerevisiae life span[J].Nature,2003,425(6954):191-196.DOI:10.1038/nature 01960.
[9] Brighton CA, Rievaj J, Kuhre RE, et al. Bile acids trigger GLP-1 release predominantly by accessing basolaterally located G protein-coupled bile acid receptors[J].Endocrinology,2015,156(11):3961-3970. DOI:10.1210/en.2015-1321.
[10] Kabra N, Li Z, Chen L,et al. SirT1 is an inhibitor of proliferation and tumor formation in colon cancer[J].J Biol Chem,2009,284(27):18210-18217. DOI:10.1074/jbc.M109.000034.
[11] Benard A, Goossens-Beumer IJ, van Hoesel AQ, et al. Nuclear expression of histone deacetylases and their histone modifications predicts clinicaloutcome in colorectal cancer[J].Histopathology,2015,66(2):270-282. DOI:10.1111/his.12534.
[12] Di Sante G, Pestell TG, Casimiro MC,et al. Loss of Sirt1 promotes prostatic intraepithelial neoplasia, reduces mitophagy, and delays PARK2 translocation to mitochondria[J].Am J Pathol,2015,185(1):266-279. DOI:10.1016/j.ajpath.2014.09.014.
[13] Jang SH, Min KW, Paik SS,et al. Loss of SIRT1 histone deacetylase expression associates with tumour progression in colorectaladenocarcinoma[J].J Clin Pathol,2012,65(8):735-739. DOI:10.1136/jclinpath-2012-200685.
[14] Herranz D, Mun`oz-Martin M, Can`amero M,et al. Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer[J].Nat Commun,2010,1:3.DOI:10.1038/ncomms1001.
[15] Cho IR, Koh SS, Malilas W,et al. SIRT1 inhibits proliferation of pancreatic cancer cells expressing pancreatic adenocarcinoma up-regulated factor(PAUF), a novel oncogene, by suppression of β-catenin[J].Biochem Biophys Res Commun,2012,423(2):270-275. DOI:10.1016/j.bbrc.2012.05.107.
[16] Dabrowski M, Szymańska-Garbacz E, Miszczyszyn Z,et al. Risk factors for cancer development in type 2 diabetes: a retrospective case-control study[J].BMC Cancer,2016,16(1):785.DOI:10.1186/s12885-016-2836-6.
[17] Ye X, Li M, Hou T, et al. Sirtuins in glucose and lipid metabolism[J].Oncotarget,2017,8(1):1845-1859. DOI:10.18632/oncotarget.12157.
[18] Kitada M, Kume S, Kanasaki K, et al. Sirtuins as possible drug targets in type 2 diabetes[J]. Curr Drug Targets,2013,14(6):622-636.
[19] Sun W, Lu J, Wu S,et al. Association of insulin resistance with breast, ovarian, endometrial and cervical cancers in non-diabetic women[J].Am J Cancer Res,2016,6(10):2334-2344.
[20] 张果,李小平,王建六,等.子宫内膜癌细胞和组织中胰岛素受体亚型的表达及作用的初步探讨[J].中华妇产科杂志,2012,47(11):839-845.DOI:10.3760/cma.j.issn.0529-567x.2012.11.009.
[21] 余娇娇, 花芳, 胡卓伟.糖尿病促进肿瘤发生发展的研究进展[J].药学学报, 2016, 51(7): 1017-1024.DOI:10.16438/j.0513-4870.2016_0254.
[22] Cao Y, Jiang X, Ma H,et al. SIRT1 and insulin resistance[J].J Diabetes Complications,2016,30(1):178-183.DOI:10.1016/j.jdiacomp.2015.08.022.
[23] Cöté CD, Rasmussen BA, Duca FA, et al. Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network[J].Nat Med,2015,21(5):498-505. DOI:10.1038/nm.3821.
[24] Yang P, Guo L, Duan ZJ,et al. Histone methyltransferase NSD2/MMSET mediates constitutive NF-κB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop[J].Mol Cell Biol,2012,32(15):3121-3131. DOI:10.1128/MCB.00204-12.
[25] Yang Q, Wang B, Gao W, et al. SIRT1 is downregulated in gastric cancer and leads to G1-phase arrest via NF-κB/cyclin d1signaling[J].Mol Cancer Res,2013,11(12):1497-1507. DOI:10.1158/1541-7786.MCR-13-0214.
[26] Jiang K, Lyu L, Shen Z, et al. Overexpression of SIRT1 is a poor prognostic factor for advanced colorectal cancer[J].Chin Med J(Engl),2014,127(11):2021-2024.

相似文献/References:

[1]赵紫琴,雒瑢,田凤石,等.替米沙坦对OLETF大鼠皮下和内脏脂肪组织PPARγ表达的影响[J].国际内分泌代谢杂志,2014,(06):365.[doi:10.3760/cma.j.issn.1673-4157.2014.06.002]
 Zhao Ziqin*,Luo Rong,Tian Fengshi,et al.Effects of telmisartan on expression of PPARγ in subcutaneous and visceral adipose tissue in OLETF rats[J].International Journal of Endocrinology and Metabolism,2014,(06):365.[doi:10.3760/cma.j.issn.1673-4157.2014.06.002]
[2]姚霜霜,张翼飞,张志国,等.小檗碱改善代谢性疾病的肠道相关机制[J].国际内分泌代谢杂志,2014,(06):386.[doi:10.3760/cma.j.issn.1673-4157.2014.06.007]
 Yao Shuangshuang,Zhang Yifei,Zhang Zhiguo,et al.The gut-related mechanisms of berberine in the treatment of metabolic diseases[J].International Journal of Endocrinology and Metabolism,2014,(06):386.[doi:10.3760/cma.j.issn.1673-4157.2014.06.007]
[3]曹萌 韦晓 刘超.自噬与胰岛β细胞功能及2型糖尿病[J].国际内分泌代谢杂志,2015,(01):53.[doi:10.3760/cma.j.issn.1673-4157.2015.01.013]
 Cao Meng,Wei Xiao,Liu Chao..Relationship between autophagy and islet β cells function, type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(06):53.[doi:10.3760/cma.j.issn.1673-4157.2015.01.013]
[4]刘艳 田秀标 韩颖.GLP-1受体激动剂呈葡萄糖依赖性刺激胰岛β细胞胰岛素分泌的机制[J].国际内分泌代谢杂志,2015,(01):66.[doi:10.3760/cma.j.issn.1673-4157.2015.01.017]
 Liu Yan*,Tian Xiubiao,Han Ying..Mechanism of GLP-1 receptor agonists in the stimulation of insulin secretion of islet β cell in a glucose-dependent manner[J].International Journal of Endocrinology and Metabolism,2015,(06):66.[doi:10.3760/cma.j.issn.1673-4157.2015.01.017]
[5]齐利琴,刘礼斌.GLP-1在2型糖尿病诱发的阿尔茨海默病治疗中的作用[J].国际内分泌代谢杂志,2016,36(01):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
 Qi Liqin,Liu Libin..Effects of GLP-1 in the treatment of Alzheimer's disease induced by type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2016,36(06):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
[6]梅稳,向光大,卢俊颜,等.GDF11对ApoE-/-糖尿病小鼠内皮依赖性 血管舒张功能的作用[J].国际内分泌代谢杂志,2016,36(02):101.[doi:10.3760/cma.j.issn.1673-4157.2016.02.007]
 Mei Wen*,Xiang Guangda,Lu Junyan,et al.Effects of GDF11 on endothelium-dependent vasodiation function of aorta in ApoE-/- diabetic mice[J].International Journal of Endocrinology and Metabolism,2016,36(06):101.[doi:10.3760/cma.j.issn.1673-4157.2016.02.007]
[7]殷俏,张云良,郭淑芹,等.视黄醇结合蛋白4、超敏C反应蛋白 与糖尿病视网膜病变的关系[J].国际内分泌代谢杂志,2016,36(03):149.[doi:10.3760/cma.j.issn.1673-4157.2016.03.02]
 Yin Qiao,Zhang Yunliang,Guo Shuqin,et al.Relationship of retinol binding protein 4 and high sensitive C-reactive protein with diabetic retinopathy[J].International Journal of Endocrinology and Metabolism,2016,36(06):149.[doi:10.3760/cma.j.issn.1673-4157.2016.03.02]
[8]王涛,张洁,祁范范,等.不同糖耐量人群血清25(OH)D3水平 及与胰岛β细胞功能的关系[J].国际内分泌代谢杂志,2016,36(04):226.[doi:10.3760/cma.j.issn.1673-4157.2016.04.04]
 Wang Tao*,Zhang Jie,Qi Fanfan,et al.Relationship between serum 25(OH)D3 level and islet β cell function in individuals with different glucose tolerance[J].International Journal of Endocrinology and Metabolism,2016,36(06):226.[doi:10.3760/cma.j.issn.1673-4157.2016.04.04]
[9]陈双双,王楚媛,孔令芳.铬与2型糖尿病[J].国际内分泌代谢杂志,2016,36(04):272.[doi:10.3760/cma.j.issn.1673-4157.2016.04.13]
 Chen Shuangshuang,Wang Chuyuan,Kong Lingfang.Chromium and type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2016,36(06):272.[doi:10.3760/cma.j.issn.1673-4157.2016.04.13]
[10]涂萍,许婷,段鹏,等.25-羟维生素D3补充对绝经后2型糖尿病 患者胰岛素敏感性及血糖控制的影响[J].国际内分泌代谢杂志,2016,36(05):299.[doi:10.3760/cma.j.issn.1673-4157.2016.05.04]
 Tu Ping,Xu Ting,Duan Peng,et al.Influence of 25-hydroxyvitamin D3 supplement on insulin sensitivity and glucose control in postmenopausal patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2016,36(06):299.[doi:10.3760/cma.j.issn.1673-4157.2016.05.04]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(81373864,81473472,81603461); 天津市自然科学基金重点项目(15JCYBJC50300)
通信作者:杨菊红,Email: megii0315@126.com
更新日期/Last Update: 2017-11-30